Studie SHIFT (the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial) a její přínos pro léčbu srdečního selhání

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Title in English	The SHIFT study (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial) and its benefit for heart failure treatment
Authors	VÍTOVEC Jiří ŠPINAR Jindřich
Year of publication	2011
Type	Article in Periodical
Magazine / Source	Intervenční a akutní kardiologie
MU Faculty or unit	Faculty of Medicine
Citation
Field	Cardiovascular diseases incl. cardiosurgery
Keywords	heart failure; ivabradine; heart rate
Description	The SHIFT study compared the effect of ivabradine with that of placebo in 6,558 patients with heart failure of ischaemic as well as nonischaemic aetiology, functional classification NYHA II-IV, with a resting heart rate above 70 bpm who received an optimal treatment for heart failure, including a maximum tolerated dose of beta blockers. The study has shown a significant reduction in the risk of the primary endpoint of cardiovascular mortality and hospitalization for heart failure by 18% in the group treated with ivabradine. Also, there was a decrease in the risk of death from heart failure by 26% in the active treated group. The decrease in hospitalization rate for heart failure was similar. Ivabradine was well tolerated with minimal side effects.
Related projects:	Early diagnostics and treatment of cardiovascular diseases